气喘市场:KOL的洞察
年间契约型资讯服务
商品编码
1422230

气喘市场:KOL的洞察

Asthma - KOL Insight

出版日期: 年间契约型资讯服务 | 出版商: FirstWord Group | 英文

价格
简介目录

本报告提供全球气喘市场相关调查,提供市场概要,以及已上市治疗方法,开发平台趋势,未来预测等资讯。

目录

摘要整理

治疗流程

调查目的

生物学的疗法

  • 已通过核准治疗方法
    • 抗 IL5 疗法:Nucala(美泊利单抗;GSK)和 Fasenra(贝那利珠单抗;阿斯特捷利康)
    • 抗 IL4/IL13 疗法:Dupixent(Dupilumab、Regeneron/Sanofi)
    • 抗 TSLP 疗法:Tezspire(tezepelumab、Amgen/AstraZeneca)
  • 开发平台(管线)的治疗方法
    • 抗 IL5 疗法:depemokimab(GSK3511294;GSK)

ICS/LABA/LAMA三倍联合治疗

    • Trelegy Ellipta(糠酸氟替卡松/umeclidinium/vilanterol;GSK)、Enerzair Breezhaler(格隆铵/?达特罗/莫米松;诺华)、Trimbow(倍氯米松/福莫特罗/格隆铵; Chiesi)(8)
  • 开发平台(管线)的治疗方法
    • Breztri/Trixeo Aerosphere(Budesonide/Budesonide/gurikopironiumu;AstraZeneca)(10)

双重固定联合治疗

  • 已通过核准治疗方法
    • Airsupra(沙丁胺醇[沙丁胺醇]/布地奈德;阿斯特捷利康/Avillion)
  • 管道处理
    • TEV-56248(硫酸沙丁胺醇/丙酸氟替卡松;Teva)

其他的作用机制

  • 开发平台(管线)的治疗方法
    • 右旋普拉克索 (Areteia Therapeutics)

未来的治疗范例

附录

KOL报告书

简介目录

Why do KOLs say GSK's next-generation anti-IL5 mAb depemokimab has the potential to impact the uptake of the established anti-IL5 therapies? What factors are hindering the initial uptake of AstraZeneca/Amgen's novel anti-TSLP mAb, Tezspire, and what could shape its future? Why are KOLs positive about the value of Sanofi/Regeneron's Dupixent in paediatric therapy? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (9)

Biologic therapies (43)

  • Approved therapies (34)
    • Anti-IL5 therapies: Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (8)
    • Anti-IL4/IL13 therapies: Dupixent (dupilumab; Regeneron/Sanofi) (12)
    • Anti-TSLP therapies: Tezspire (tezepelumab; Amgen/AstraZeneca) (14)
  • Pipeline therapies (9)
    • Anti-IL5 therapies: depemokimab (GSK3511294; GSK) (9)

ICS/LABA/LAMA triple combination therapies (18)

  • Approved therapies (8)
    • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK), Enerzair Breezhaler (glycopyrronium/indacaterol/mometasone; Novartis) and Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi) (8)
  • Pipeline therapies (10)
    • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrronium; AstraZeneca) (10)

Dual fixed-combination therapies (21)

  • Approved therapies (11)
    • Airsupra (salbutamol [albuterol]/budesonide; AstraZeneca/Avillion) (11)
  • Pipeline therapies (10)
    • TEV-56248 (albuterol sulfate/fluticasone propionate; Teva) (10)

Other mechanisms of action (11)

  • Pipeline therapies (11)
    • Dexpramipexole (Areteia Therapeutics) (11)

Future treatment paradigm (9)

  • Key insights summary (9)

Appendix (4)

  • KOL details (4)
    • KOLs from the USA (1)
    • KOLs from Europe (2)